Here are the 8-K filings from Dalrada Technology Group (DHTI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow DHTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DHTI filings page.
Dalrada Technology Group, Inc. (DHTI) paid IBS Equity Fund III, LLC and IBS Private Credit Fund IV, LLC a $20,000 lump-sum settlement on October 2, 2026, when the settlement closed. Genefic, Inc., Dalrada’s wholly owned subsidiary, and certain affiliates and subsidiaries were also parties. IBS had provided no funding under the financing documents; in September 2026, it asserted events of default and demanded approximately $1,162,246, which Dalrada disputed.
At closing, the financing documents terminated and related obligations were discharged; the secured promissory note and pre-funded warrant were cancelled. Dalrada’s corporate guaranty, Brian Bonar’s personal guaranty, and IBS’s liens, security interests and account-control rights were released. IBS withdrew its notices and asserted enforcement steps. Mutual releases cover claims relating to the financing documents and notices, subject to stated exclusions; each party bears its own attorneys’ fees and expenses.
On October 5, 2026, IBS confirmed receipt of the settlement, withdrawal of the notices, termination of the financing documents and release of security interests. A termination statement was filed with the Wyoming Secretary of State. Dalrada stated that no amounts remained owing to IBS and no IBS indebtedness, guaranty, lien or equity right remained outstanding. The agreement provides for mutual non-admission and does not constitute an admission of default, liability or wrongdoing.
Dalrada Technology Group, Inc. (DHTI) reports that its wholly owned subsidiary Genefic, Inc. and related affiliates entered into a $20,000,000 Master Performance Standby Letter of Credit and Guaranty Agreement and a $5,000,000 Master Credit, Security, and Account Purchase Agreement with IBS entities effective December 31, 2025, but received no funding under these facilities.
After Genefic elected to terminate the financing relationship, IBS declared Events of Default, accelerated a secured promissory note, and demanded various fees and charges, asserting a total of $1,162,246 (exclusive of interest and additional costs) plus additional qualifying collateral of not less than $875,000. IBS has also reserved extensive remedies, including potential control over deposit accounts, receivables, and pledged equity interests, and has issued default notices to Dalrada as corporate guarantor and to Brian Bonar as personal guarantor.
Dalrada disputes the asserted Events of Default, the demanded amounts, and the early termination fees, emphasizing that no funding was ever provided under the agreements. The company believes it has meritorious defenses and intends to vigorously contest IBS’s claims, while cautioning that if IBS were to prevail or exercise its reserved remedies, this could have a material adverse effect on Dalrada’s liquidity, financial condition, results of operations, and on Genefic’s operations, and could trigger defaults under other indebtedness.
Dalrada Technology Group, Inc. reported that it and certain subsidiaries received a notice of default on multiple credit facilities from Nautilus entities on April 24, 2026. The lender cites missed required payments and is demanding a $500,000 cure payment by May 1, 2026.
If the cure is not made, the lender may accelerate the loan balances and begin enforcement actions under the term loan and factoring agreements. Dalrada is reviewing the notice and plans to discuss potential resolutions, but states there is no assurance the defaults will be cured or that acceleration and enforcement will be avoided.
Dalrada Technology Group, through its subsidiary Genefic Inc., amended a prior report to clarify that new financing agreements create up to $25,000,000 in aggregate commitments, not $20,000,000 as first disclosed. The package combines up to $20,000,000 of standby letters of credit and related guarantees with a linked $5,000,000 revolving accounts receivable facility supporting Genefic’s healthcare operations.
The facilities run from December 31, 2025 to December 31, 2030 and are secured by first-priority liens on substantially all assets of Genefic and the parent company, plus a pledge of 100% of equity in all subsidiaries. Chairman and CEO Brian Bonar has provided an unlimited personal guaranty that is joint and several with the company’s obligations, and the board highlights resulting conflicts of interest between his personal exposure and his duties to shareholders. Upfront consideration includes $140,000 in cash, a $165,000 promissory note, and a pre-funded warrant valued at $225,000.
Dalrada Technology Group, through its wholly owned subsidiary Genefic Inc., entered into a financing structure providing up to $20,000,000 in guarantees and related credit support with IBS-affiliated funds. A related receivables-based revolving facility may provide up to $5,000,000 in funding for Genefic’s healthcare operations.
The arrangements are secured by first-priority liens on substantially all assets of Genefic and a first-priority security interest in substantially all assets of Dalrada, plus a pledge of 100% of the equity in all Dalrada subsidiaries. CEO Brian Bonar also provided an unlimited personal guaranty of Genefic’s obligations, which the Board identified as creating multiple potential conflicts of interest. Dalrada did not receive separate consideration for its upstream guarantee beyond benefits to Genefic.
Dalrada Technology Group, Inc. filed a current report to share that its Chief Executive Officer and Chairman, Brian Bonar, issued an open letter to shareholders dated January 20, 2026. The letter reviews the company’s 2025 performance, discusses operational progress in its core markets of renewable energy and heat pumps, atmospheric water generators, and semiconductor deposition solutions, and highlights recent partnerships, installations, and restructuring efforts. It also outlines Dalrada’s strategic focus and outlook for 2026 and beyond. The letter is included as Exhibit 99.1 and is furnished, rather than filed, under the securities laws.